Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Hepatobiliary disorders – page 5

  • 357 clinical trials
  • 141 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Hepatocellular carcinoma89Cholangiocarcinoma38Hepatic cirrhosis25Metabolic dysfunction-associated steatohepatitis22Colorectal cancer20Non-alcoholic steatohepatitis17Chronic hepatitis B16Hepatitis D14Primary biliary cholangitis14Cholangitis sclerosing12Endometrial cancer12Non-small cell lung cancer12Alpha-1 antitrypsin deficiency11Gastric cancer11Malignant melanoma11Biliary neoplasm10Hepatitis B10Breast cancer9Ovarian cancer9Bile duct cancer8Gallbladder cancer8Hepatic cancer8Pancreatic carcinoma8Adenocarcinoma pancreas7+215

Clinical trials in Hepatobiliary disorders

357 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

357 clinical trials

Hepatoblastoma+1

Recruiting

Study on the Safety and Effectiveness of Patritumab Deruxtecan for Children with Relapsed or Refractory Hepatoblastoma and Rhabdomyosarcoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Dexamethasone
  • Sponsor:Merck Sharp & Dohme LLC

HER2 positive biliary tract cancer

Recruiting

Study of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

Hepatitis B

Recruiting

Study on the Safety and Immune-Enhancing Effects of Pomalidomide in Patients with Chronic Hepatitis B Infection

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Pomalidomide
  • Sponsor:Region Midtjylland

Alagille syndrome+1

Recruiting

Study on Long-Term Safety and Effects of Maralixibat for Patients with Alagille Syndrome

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:MARALIXIBAT
  • Sponsor:Mirum Pharmaceuticals Inc.

Cholecystitis acute

Recruiting

Study on Preoperative Antibiotics for Patients with Acute Cholecystitis: Comparing Ertapenem, Ciprofloxacin, and Cefuroxime

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Cefuroxime
  • Sponsor:HUS-Yhtymae

Hepatic cirrhosis

Recruiting

Study on the Effect of Carvedilol for Patients with Cirrhotic Portal Hypertension

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carvedilol
  • Sponsor:University Hospital Of Clermont-Ferrand

Metabolic dysfunction-associated steatohepatitis

Recruiting

Study on Liver Fibrosis Assessment Using 68Ga-FAPI-46 Imaging in Patients with Suspected or Confirmed Nonalcoholic Steatohepatitis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:CHRU De Nancy

Hepatitis alcoholic

Recruiting

Study on the Effects of Alpha-1 Antitrypsin and Prednisolone in Patients with Severe Alcohol-Related Hepatitis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Medizinische Universitaet Innsbruck

Hepatic cirrhosis

Recruiting

Study on Fecal Microbiome Transplantation for Patients with Decompensated Cirrhosis Using Allogeneic Fecal Microbiota Capsules

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Consorcio Centro De Investigacion Biomedica En Red

Porto-sinusoidal vascular disorder

Recruiting

Study on the Safety of Edoxaban for Patients with Porto-Sinusoidal Vascular Disorder

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Edoxaban
  • Sponsor:Medical University Of Vienna

Cirrhosis alcoholic

Recruiting

Study on Carvedilol for Preventing Complications in Patients with Early-Stage Cirrhosis and High Blood Pressure in the Liver

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carvedilol
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Hepatocellular carcinoma+1

Recruiting

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Substances studied in this area

The therapies tested most often in Hepatobiliary disorders trials.

Durvalumab37 clinical trialsBevacizumab29 clinical trialsAtezolizumab27 clinical trialsCisplatin26 clinical trialsLenvatinib22 clinical trialsTremelimumab22 clinical trialsGemcitabine20 clinical trialsInfliximab15 clinical trialsMycophenolate Mofetil15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.